Disclosures: Hiroshi Horie: Nothing to Disclose, Ken Fukumitsu: Nothing to Disclose, Kentaro Iwaki: Nothing to Disclose, Fumiaki Munekage: Nothing to Disclose, Kenta Makino: Nothing to Disclose, Katsuhiro Tomofuji: Nothing to Disclose, Hidenobu Kojima: Nothing to Disclose, Elena Uebayashi: Nothing to Disclose, Satoshi Ogiso: Nothing to Disclose, Takamichi Ishii: Nothing to Disclose, Etsuro Hatano: Nothing to Disclose 2076 THE PPAR-DELTA AGONIST SELADELPAR NORMALIZES PRIMARY BILIARY CHOLANGITIS-LIKE FEATURES IN HUMAN CHOLANGIOCYTES AND REDUCES PATHOLOGICAL IMMUNE ACTIVATION Francisco Caballero-Camino 1 Irune Lasa 2 Ainhoa Lapitz 1 Xia Wu 3 Pedro Rodrigues 1 Noelia Pastor-Toyos 1 Laura Izquierdo-Sanchez 1 Jiangao Song 3 Edward Cable 3 Jeffrey Johnson 3 Yun-Jung Choi 3 Charles McWherter 3 Jesus Banales 1 , 1 Biogipuzkoa Health Research Institute, Donostia University Hospital,University of the Basque Country, 2 Biogipuzkoa Health Research Institute,Donostia University Hospital,University of the Basque Country, 3 CymaBay Therapeutics Background: Primary biliary cholangitis (PBC) is a chronic cholestatic and immune-mediated liver disease characterized by the progressive impairment and destruction of bile duct epithelial cells (i.e., cholangiocytes)
The new STAT Clinic for Head & Neck Cancer opened on the campus of Wellstar North Fulton Medical Center on August 11, 2022
PMCID: PMC11561716
Wegovy also has an FDA approval for cardiovascular risk reduction (March 2024), which makes it attractive for coverage
.png)
